benzyl N-[(1Z)-1-amino-1-hydroxyimino-2-methylpropan-2-yl]carbamate

We are benzyl N-[(1Z)-1-amino-1-hydroxyimino-2-methylpropan-2-yl]carbamate CAS:518047-98-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:benzyl N-[(1Z)-1-amino-1-hydroxyimino-2-methylpropan-2-yl]carbamate
CAS.NO:518047-98-8
Synonyms:benzyl N-[(1Z)-1-amino-1-hydroxyimino-2-methylpropan-2-yl]carbamate
[1-(N'-hydroxycarbamimidoyl)-1-methyl-ethyl]carbamic acid benzyl ester
Benzyl (1-amino-1-(hydroxyimino)-2-methylpropan-2-yl)carbamate
benzylhydroxycarbamimidoylmethylethylcarbamate
BENZYL[2-AMINO-2-(HYDROXYIMINO)-1,1-DIMETHYLETHYL]CARBAMATE
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Molecular Formula C12H17N3O3
Molecular Weight 251.282
 
Specification:
Appearance:White to light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Raltegravir(CAS:518048-05-0) and Raltegravir potassium(CAS:871038-72-1).

benzyl N-[(1Z)-1-amino-1-hydroxyimino-2-methylpropan-2-yl]carbamate


Related News: Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.21172-41-8 In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.119-17-5 Retrogenix’s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding.3601-90-9 According to the business type, it can be divided into non-CMO business of APIs and intermediates and CMO business of APIs and intermediates.ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.

Related Products
Product Name
D-Lysine Monohydrochloride View Details
2-Chloro-1-cyclopropyl-2-(2-fluorophenyl)ethanone View Details
(1S)-3-(dimethylamino)-1-thiophen-2-ylpropan-1-ol,(2S)-2-hydroxy-2-phenylacetic acid View Details
(2R,3R)-3-(3-Methoxyphenyl)-N,N,2-trimethylpentan-1-amine manufacturer 2-Fluoro-1,3-dimethylimidazolidinium hexafluorophosphate manufacturer (2S)-1-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid manufacturer 3-Formylphenylboronic acid manufacturer (E)-Guggulsterone manufacturer